Search
for
Sort by
Research 30 of 221
- Clinical development and management of adverse events associated with FGFR inhibitors
- Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
- An epidermis‐permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors
- ポ-トフォリオを使った社会科教育法の授業実践--ポ-トフォリオによるカリキュラム改革と教師の力量形成(2)
- Screening the Chemical Composition and Bioactivity of <i>Cerasus serrulata</i> Flower Extracts Using Two Extraction Methods
- FGF Family: From Drug Development to Clinical Application
- EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Antisense oligonucleotide targeting fibroblast growth factor receptor (FGFR)-1 stimulates cellular activity of hair follicles in an<i>in vitro</i>organ culture system
- New Activators and Inhibitors in the Hair Cycle Clock: Targeting Stem Cells’ State of Competence
- FilaggrinHigh melanomas exhibit active FGFR and allergic signatures with impaired GNA14 and Th1 signatures
- Anti-inflammatory and anti-hyperplastic effect of Bazhengsan in a male rat model of chronic nonbacterial prostatitis
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury
- The PDGF/PDGFR pathway as a drug target
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Mechanism of action of herbs and their active constituents used in hair loss treatment
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Lentiviral Arrays for Live-cell Dynamic Monitoring of Gene and Pathway Activity During Stem Cell Differentiation
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Effects of oleanolic acid on hair growth in mouse dorsal skin mediated via regulation of inflammatory cytokines
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers
- The HEDGEHOG-GLI1 pathway is important for fibroproliferative properties in keloids and as a candidate therapeutic target
- Specific inhibition of FGF5-induced cell proliferation by RNA aptamers
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
- RASopathic Skin Eruptions during Vemurafenib Therapy